PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Key Points Pfizer’s earnings and stock price soared in early pandemic days thanks to its coronavirus treatment and ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Johnson & Johnson JNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

Chinese biotech shares are surging this year on growing optimism over innovative cancer treatments being licensed to western ...

You can buy shares of Healthpeak Properties and Pfizer with well less than $100 at the moment. At the moment, anyone with ...

Pfizer’s first-quarter oncology revenues grew 7% on an operational basis, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev.

Over the past decade, Pfizer has strengthened its R&D pipeline through M&A deals and clinical trial success. Pfizer’s key vaccine candidates in late-stage studies are its C. difficile vaccine and an ...